Generation of human bispecific common light chain antibodies by combining animal immunization and yeast display
- PMID: 28062646
- DOI: 10.1093/protein/gzw077
Generation of human bispecific common light chain antibodies by combining animal immunization and yeast display
Abstract
Bispecific antibodies (bsAbs) pave the way for novel therapeutic modes of action along with potential benefits in several clinical applications. However, their generation remains challenging due to the necessity of correct pairings of two different heavy and light chains and related manufacturability issues. We describe a generic approach for the generation of fully human IgG-like bsAbs. For this, heavy chain repertoires from immunized transgenic rats were combined with either a randomly chosen common light chain or a light chain of an existing therapeutic antibody and screened for binders against tumor-related targets CEACAM5 and CEACAM6 by yeast surface display. bsAbs with subnanomolar affinities were identified, wherein each separate binding arm mediated specific binding to the respective antigen. Altogether, the described strategy represents a combination of in vivo immunization with an in vitro selection method, which allows for the integration of existing therapeutic antibodies into a bispecific format.
Keywords: antibody; bispecific antibody; common light chain; high-throughput screening; yeast surface display.
© The Author 2017. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Similar articles
-
"BIClonals": Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells.Methods Mol Biol. 2019;1904:431-454. doi: 10.1007/978-1-4939-8958-4_22. Methods Mol Biol. 2019. PMID: 30539485
-
Dual Function pH Responsive Bispecific Antibodies for Tumor Targeting and Antigen Depletion in Plasma.Front Immunol. 2019 Aug 9;10:1892. doi: 10.3389/fimmu.2019.01892. eCollection 2019. Front Immunol. 2019. PMID: 31447859 Free PMC article.
-
Nanocell targeting using engineered bispecific antibodies.MAbs. 2015;7(1):53-65. doi: 10.4161/19420862.2014.985952. MAbs. 2015. PMID: 25523746 Free PMC article.
-
Therapeutic bispecific antibodies: The selection of stable single-chain fragments to overcome engineering obstacles.IDrugs. 2010 Aug;13(8):543-9. IDrugs. 2010. PMID: 20721825 Review.
-
Engineering bispecific antibodies with defined chain pairing.N Biotechnol. 2017 Oct 25;39(Pt B):167-173. doi: 10.1016/j.nbt.2016.12.010. Epub 2017 Jan 27. N Biotechnol. 2017. PMID: 28137467 Review.
Cited by
-
An Engineered Mouse Model That Generates a Diverse Repertoire of Endogenous, High-Affinity Common Light Chain Antibodies.Antibodies (Basel). 2024 Feb 8;13(1):14. doi: 10.3390/antib13010014. Antibodies (Basel). 2024. PMID: 38390875 Free PMC article.
-
Next generation of multispecific antibody engineering.Antib Ther. 2023 Dec 8;7(1):37-52. doi: 10.1093/abt/tbad027. eCollection 2024 Jan. Antib Ther. 2023. PMID: 38235376 Review.
-
Structure and Dynamics Guiding Design of Antibody Therapeutics and Vaccines.Antibodies (Basel). 2023 Oct 18;12(4):67. doi: 10.3390/antib12040067. Antibodies (Basel). 2023. PMID: 37873864 Free PMC article. Review.
-
Conditional activation of an anti-IgM antibody-drug conjugate for precise B cell lymphoma targeting.Front Immunol. 2023 Sep 28;14:1258700. doi: 10.3389/fimmu.2023.1258700. eCollection 2023. Front Immunol. 2023. PMID: 37841262 Free PMC article.
-
Efficient production of bispecific antibody by FAST-IgTM and its application to NXT007 for the treatment of hemophilia A.MAbs. 2023 Jan-Dec;15(1):2222441. doi: 10.1080/19420862.2023.2222441. MAbs. 2023. PMID: 37339067 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
